C3.ai enters the week to September earnings with one of the sharpest divergences in its recent history — short interest remains near historically elevated levels while options traders have abruptly flipped to their most bullish stance in months.
The options signal is the most striking data point this week. The put/call ratio collapsed to 0.44 on July 17, more than two standard deviations below its 20-day average of 0.55 — the most call-heavy reading relative to recent norms in at least a year. That kind of z-score (-2.42) typically reflects an unusual burst of bullish positioning or aggressive call-buying rather than a gradual sentiment shift. It stands in sharp contrast to where the PCR was trading just a week ago, when it was running close to 0.58, well within its recent range.
Short interest tells a meaningfully different story. Bears have not capitulated. At 33.3% of the free float — roughly 44.7 million shares — short interest is high in absolute terms, even though it has been gradually easing. It fell about 4% on the week and 9% over the past month, pulled back from a peak north of 50 million shares in late June. Borrow remains almost frictionless: cost to borrow is just 0.56%, down 13% on the week, and availability is ample at 160%, meaning lenders hold roughly 1.6 shares available for every share already borrowed. That is not a market under squeeze pressure. The ORTEX short score, at 73, has dipped from its mid-week high of 74.7 but remains elevated — confirming that the aggregate short positioning picture is still meaningfully bearish even as the headline share count drifts lower. The contrast with the options market is genuine: call buyers appear optimistic, but short sellers are not rushing for the exits.
The Street broadly agrees with the bears on fundamentals. The analyst cluster that responded after the June 3 earnings print was almost uniformly cautious — Morgan Stanley maintained Underweight with a $7 target, DA Davidson held Underperform at $7, and Canaccord lifted its Hold target to $10 while keeping its neutral stance. UBS nudged its target to $12, also Neutral. The lone bull, Wedbush, reiterated Outperform at $15, though that target is now well above where the stock is trading at $8.82. The consensus price target of roughly $8.82 is almost exactly where the stock closed — an unusually precise alignment that points more to uncertainty than to conviction in either direction. The EPS surprise factor score ranks in the 89th percentile, meaning the company has beaten estimates consistently, but the short score rank sits in just the 3rd percentile, flagging extreme bearish positioning relative to universe peers. The price-to-book multiple has compressed 28% over the past month to 2.75x, and EV/EBITDA remains deeply negative at -7.9x, reflecting a company still burning cash.
The insider register adds another cautious note. Founder and Chairman/CEO Thomas Siebel sold roughly 462,000 shares across July 14 and 15, collecting just over $4.2 million — accelerating disposals that fit a pattern of steady selling near the top of the recent range. The CEO and CFO also sold in late June. Net insider activity over 90 days shows a positive share count (reflecting equity awards), but in dollar terms insiders net sold approximately $15.7 million over that window. These are not distressed sales at crisis prices, but the pace and clustering — across CEO, founder, CFO, and a director — reinforce the sense that those closest to the business are not building exposure at current levels.
After the June 3 print, AI fell 5.4% the next day and shed another 3.4% over the following week. The next earnings date is September 2. Between now and then, the tension between an unusually bullish options setup and a still-crowded short book — combined with an insider base that is selling — is the dynamic worth monitoring most closely.
See the live data behind this article on ORTEX.
Open AI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
